Prosecution Insights
Prosecution Insights
15 pending office actions • 12 art units • 14 examiners • 0 of 15 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (13%) |
| §103 only | 7 (47%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 2 (13%) |
| Multi-statute (no §101) | 3 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALDARONDO, DASIA ALI | 2 | 0.0% | +0.0% |
| SANGHERA, STEVEN G.S. | 1 | 30.0% | +29.1% |
| STONEBRAKER, ALYSSA RAE | 1 | 56.9% | +50.4% |
| DAUNER, JOSEPH G | 1 | 56.8% | +35.6% |
| GU, QINHUA | 1 | 77.3% | +27.6% |
| NGUYEN, QUANG | 1 | 38.1% | +53.0% |
| BATES, KEENAN ALEXANDER | 1 | 44.8% | +76.5% |
| FISHER, BRITTANY I | 1 | 84.3% | +12.5% |
| FRITCHMAN, REBECCA M | 1 | 45.7% | +35.8% |
| FAUST, AMBER KATHLEEN | 1 | 60.9% | +52.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19044010 | METHODS AND SYSTEMS FOR SCHEDULING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE | SANGHERA, STEVEN G.S. | 25d overdue |
| 18327651 | CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF | NGUYEN, QUANG | 18d overdue |
| 18496588 | FACTORS FOR OPTIMIZING IMMUNOTHERAPY | DAUNER, JOSEPH G | 13d |
| 18455028 | IMMUNE CELL FUNCTION | ALDARONDO, DASIA ALI | — |
| 18330962 | METHODS OF PREPARING LYMPHOCYTES FOR CELL THERAPY | ALDARONDO, DASIA ALI | — |
| 18038831 | DISPOSABLE KITS FOR CELL WASHING, MAGNETIC ISOLATION AND DOSING PREPARATION | FISHER, BRITTANY I | — |
| 17853708 | METHOD FOR IDENTIFYING VARIANTS IN GENE PRODUCTS FROM GENE CONSTRUCTS USED IN CELL THERAPY APPLICATIONS | LU, FRANK WEI MIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19044010 | METHODS AND SYSTEMS FOR SCHEDULING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE | SANGHERA, STEVEN G.S. | 25d overdue |
| 17814811 | SPLIT CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | FAUST, AMBER KATHLEEN | 23d overdue |
| 18327651 | CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF | NGUYEN, QUANG | 18d overdue |
| 17816076 | MONITORING AND MANAGEMENT OF CELL THERAPY-INDUCED TOXICITIES | FRITCHMAN, REBECCA M | 8d overdue |
| 18496588 | FACTORS FOR OPTIMIZING IMMUNOTHERAPY | DAUNER, JOSEPH G | 13d |
| 18531896 | FLOW CYTOMETRIC METHOD FOR CHARACTERIZATION OF T-CELL IMPURITIES | STONEBRAKER, ALYSSA RAE | — |
| 18377685 | LARGE SCALE CAR-T IMMUNE CELL MANUFACTURING METHOD UTILIZING LENTIVIRAL VECTOR TRANSFECTION | GU, QINHUA | — |
| 18038858 | METHODS FOR CELL ACTIVATION, TRANSDUCTION AND EXPANSION | BATES, KEENAN ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1631 | 2 |
| 1644 | 2 |
| 3684 | 1 |
| 1642 | 1 |
| 1682 | 1 |
| 1633 | 1 |
| 1796 | 1 |
| 1758 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19044010 | METHODS AND SYSTEMS FOR SCHEDULING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE | SANGHERA, STEVEN G.S. | 3684 | §101§103§112 | Final Rejection | 25d overdue | Pending | Feb 03, 2025 |
| 18531896 | FLOW CYTOMETRIC METHOD FOR CHARACTERIZATION OF T-CELL IMPURITIES | STONEBRAKER, ALYSSA RAE | 1642 | §103 | Final Rejection | — | Pending | Dec 07, 2023 |
| 18496588 | FACTORS FOR OPTIMIZING IMMUNOTHERAPY | DAUNER, JOSEPH G | 1682 | §101§103§112 | Final Rejection | 13d | Pending | Oct 27, 2023 |
| 18377685 | LARGE SCALE CAR-T IMMUNE CELL MANUFACTURING METHOD UTILIZING LENTIVIRAL VECTOR TRANSFECTION | GU, QINHUA | 1633 | §103 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18455028 | IMMUNE CELL FUNCTION | ALDARONDO, DASIA ALI | 1647 | §103 | Final Rejection | — | Pending | Aug 24, 2023 |
| 18330962 | METHODS OF PREPARING LYMPHOCYTES FOR CELL THERAPY | ALDARONDO, DASIA ALI | 1647 | §103 | Final Rejection | — | Pending | Jun 07, 2023 |
| 18327651 | CHIMERIC TRANSMEMBRANE PROTEINS AND USES THEREOF | NGUYEN, QUANG | 1631 | §102§103§112 | Non-Final OA | 18d overdue | Pending | Jun 01, 2023 |
| 18038858 | METHODS FOR CELL ACTIVATION, TRANSDUCTION AND EXPANSION | BATES, KEENAN ALEXANDER | 1631 | §103DP | Non-Final OA | — | Pending | May 25, 2023 |
| 18038831 | DISPOSABLE KITS FOR CELL WASHING, MAGNETIC ISOLATION AND DOSING PREPARATION | FISHER, BRITTANY I | 1796 | §102§103§112 | Non-Final OA | — | Pending | May 25, 2023 |
| 17816076 | MONITORING AND MANAGEMENT OF CELL THERAPY-INDUCED TOXICITIES | FRITCHMAN, REBECCA M | 1758 | §103 | Final Rejection | 8d overdue | Pending | Jul 29, 2022 |
| 17814811 | SPLIT CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | FAUST, AMBER KATHLEEN | 1643 | DP | Final Rejection | 23d overdue | Pending | Jul 25, 2022 |
| 17852918 | CLOSED-SYSTEM AND METHOD FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING | SKELDING, ZACHARY S | 1644 | §103 | Final Rejection | 60d overdue | Pending | Jun 29, 2022 |
| 17853708 | METHOD FOR IDENTIFYING VARIANTS IN GENE PRODUCTS FROM GENE CONSTRUCTS USED IN CELL THERAPY APPLICATIONS | LU, FRANK WEI MIN | 1600 | §103§112 | Non-Final OA | — | Pending | Jun 29, 2022 |
| 17774720 | CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | JOHANSEN, PETER N. | 1644 | §102§103DP | Final Rejection | — | Pending | May 05, 2022 |
| 17679521 | METHODS AND SYSTEMS FOR PERFORMING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE WITH CHAIN-OF-CUSTODY AND CHAIN-OF-IDENTITY BIOLOGICAL SAMPLE TRACKING | WANG, RUIXUE | 1672 | §103 | Non-Final OA | 31d overdue | Pending | Feb 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial